herpes zoster vaccine (recombinant, adjuvanted)

This medicine is authorised for use in the European Union.


Shingrix is a vaccine used in adults aged 50 years and over to protect against shingles (herpes zoster) and post-herpetic neuralgia (long-lasting nerve pain following shingles). It can also be used from the age of 18 years and over in adults who are at increased risk of herpes zoster.

Shingles is a painful, blistering rash caused by the reactivation of the virus that causes chickenpox. After a patient has had chickenpox, the virus can lie dormant in the nerves and become active again if the immune system (the body’s natural defences) weakens due, for example, to ageing or to an illness.

Shingrix contains a protein (glycoprotein E) from varicella zoster virus, the virus that causes chickenpox.

This EPAR was last updated on 28/09/2020

Authorisation details

Product details
Agency product number
Active substance
Recombinant varicella zoster virus glycoprotein E
International non-proprietary name (INN) or common name
herpes zoster vaccine (recombinant, adjuvanted)
Therapeutic area (MeSH)
Herpes Zoster
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
GlaxoSmithkline Biologicals SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Rue de l'Institut 89
1330 Rixensart

Product information

25/08/2020 Shingrix - EMEA/H/C/004336 - II/0022


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:

  • adults 50 years of age or older;
  • adults 18 years of age or older at increased risk of HZ.

The use of Shingrix should be in accordance with official recommendations.

Assessment history

How useful was this page?

Add your rating
2 ratings
4 ratings
1 rating
2 ratings